C-Reactive Protein (CRP) in Obese Diabetic Women

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Mexican National Institute of Public Health
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Menopausal

• Diagnosed diabetes mellitus type 2

• Obese (body mass index [BMI] > 25 ≤ 30)

Exclusion Criteria:

• Fasting blood glucose ≥ 200 mg/dl

• CRP < 2 mg/L and > 10 mg/L